Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Nov 8;12(22):6985.
doi: 10.3390/jcm12226985.

Second Generation Long-Acting Injectable Antipsychotics in Schizophrenia: The Patient's Subjective Quality of Life, Well-Being, and Satisfaction

Claudio Brasso  1 , Silvio Bellino  1 , Paola Bozzatello  1 , Cristiana Montemagni  1 , Marco Giuseppe Alberto Nobili  1 , Rodolfo Sgro  1 , Paola Rocca  1
Affiliations
Review

Second Generation Long-Acting Injectable Antipsychotics in Schizophrenia: The Patient's Subjective Quality of Life, Well-Being, and Satisfaction

Claudio Brasso et al. J Clin Med. .

Abstract

Schizophrenia (SZ) is among the twenty most disabling diseases worldwide. Subjective quality of life, well-being, and satisfaction are core elements to achieving personal recovery from the disorder. Long-acting injectable second-generation antipsychotics (SGA-LAIs) represent a valid therapeutic option for the treatment of SZ as they guarantee good efficacy and adherence to treatment. The aim of this rapid review is to summarize the evidence on the efficacy of SGA-LAIs in improving subjective quality of life, well-being, and satisfaction. The PubMed database was searched for original studies using SGA, LAI, risperidone, paliperidone, aripiprazole, olanzapine, SZ, and psychosis as keywords. Twenty-one studies were included: 13 clinical trials, 7 observational studies, and 1 post hoc analysis. It has been shown that SGA-LAIs bring an improvement to specific domains of subjective and self-rated quality of life, well-being, or satisfaction in prospective observational studies without a control arm and in randomized controlled trials versus placebo. The superiority of SGA-LAIs as compared with oral equivalents and haloperidol-LAI has been reported by some randomized controlled and observational studies. Although promising, the evidence is still limited because of the lack of studies and several methodological issues concerning the choice of the sample, the evaluation of the outcome variables, and the study design. New methodologically sound studies are needed.

Keywords: LAI; adherence; aripiprazole; olanzapine; paliperidone palmitate; personal recovery; psychosis; rapid review; risperidone.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Flowchart of the selection process of the articles included. * No automation tools were used. SGA-LAIs: long-acting injectable second-generation antipsychotics; RCT: randomized clinical trials.
Figure 2
Figure 2
Flowchart of the risk of bias assessment procedure [64,71,72].
Figure 3
Figure 3
Results of the risk of bias assessment [28,29,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91].
See this image and copyright information in PMC

References

    1. Leucht S., Schneider-Thoma J., Burschinski A., Peter N., Wang D., Dong S., Huhn M., Nikolakopoulou A., Salanti G., Davis J.M. Long-term Efficacy of Antipsychotic Drugs in Initially Acutely Ill Adults with Schizophrenia: Systematic Review and Network Meta-analysis. World Psychiatry. 2023;22:315–324. doi: 10.1002/wps.21089. - DOI - PMC - PubMed
    1. Lin D., Thompson-Leduc P., Ghelerter I., Nguyen H., Lafeuille M.-H., Benson C., Mavros P., Lefebvre P. Real-World Evidence of the Clinical and Economic Impact of Long-Acting Injectable Versus Oral Antipsychotics among Patients with Schizophrenia in the United States: A Systematic Review and Meta-Analysis. CNS Drugs. 2021;35:469–481. doi: 10.1007/s40263-021-00815-y. - DOI - PMC - PubMed
    1. Fabrazzo M., Cipolla S., Camerlengo A., Perris F., Catapano F. Second-Generation Antipsychotics’ Effectiveness and Tolerability: A Review of Real-World Studies in Patients with Schizophrenia and Related Disorders. J. Clin. Med. 2022;11:4530. doi: 10.3390/jcm11154530. - DOI - PMC - PubMed
    1. Faden J., Citrome L. Schizophrenia: One Name, Many Different Manifestations. Med. Clin. N. Am. 2023;107:61–72. doi: 10.1016/j.mcna.2022.05.005. - DOI - PubMed
    1. MacEwan J.P., Forma F.M., Shafrin J., Hatch A., Lakdawalla D.N., Lindenmayer J.-P. Patterns of Adherence to Oral Atypical Antipsychotics among Patients Diagnosed with Schizophrenia. J. Manag. Care Spec. Pharm. 2016;22:1349–1361. doi: 10.18553/jmcp.2016.22.11.1349. - DOI - PMC - PubMed

LinkOut - more resources